MYOV - Clovis Rubraca Data And Other News: The Good Bad And Ugly Of Biopharma
Clovis reports positive data from TRITON clinical trial
Clovis Oncology Inc. (CLVS) announced additional data from the Phase 2 TRITON2 study of its lead drug candidate Rubraca for treating metastatic castration-resistant prostate cancer harboring BRCA1/2 mutations. The data corroborated with the FDA's accelerated approval of Rubraca for treating mCRPC patients with a deleterious BRCA mutation and who have previously been administered androgen receptor-directed therapy and taxane-based chemotherapy.
Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3. The drug candidate is currently being developed for treating a wide range of tumors